GSK · Pharma and healthcare · one day
GSK (GSK): news on Monday 26 October 2026
News from the 24 hours to Monday morning, 26 October 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage focused on GSK's cancer pipeline, including strong response-rate data, its ovarian cancer drug at ESMO and a licensing deal with HUTCHMED. The tone leans positive, though the ovarian cancer field is described as crowded.
What drove it
- oncology trial data
- HUTCHMED licensing deal
- AI drug-safety strategy
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Tue 20 Oct | +8.3 | 37 |
| Wed 21 Oct | +10.0 | 26 |
| Thu 22 Oct | +10.0 | 37 |
| Fri 23 Oct | +7.2 | 18 |
| Sat 24 Oct | +8.0 | 15 |
| Sun 25 Oct | +2.0 | 6 |
| Mon 26 Oct | +5.7 | 5 |
3 stories · 5 headlines · strongest first
Pharma and healthcare on 26 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| GSK shares ovarian cancer data on mo-rez at ESMO +6.72 headlines today · 4 in all, since 25 October · Reports cover 76 percent complete responses and the ADC field. | ||
| +8.7 | Reports strong 76 percent complete response data for GSK. | |
| +3.0 | Covers GSK's ovarian cancer ADC at ESMO; competitive field tempers optimism. | |
| GSK share and AI commentary +5.32 headlines today · Pieces discuss GSK doubters and its drug-safety AI strategy. | ||
| +6.0 | Suggests sceptics were wrong about GSK, favourable framing. | |
| +4.5 | Positive feature on GSK's AI approach to drug safety. | |
| HUTCHMED licensing deal with GSK closes +5.81 headline today · 12 in all, since 15 October · Yahoo Finance discusses what the GSK deal means for HUTCHMED shareholders. | ||
| +5.2 | GSK licensing deal with HUTCHMED, a pipeline-expanding move. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.